A1 Refereed original research article in a scientific journal

NRF2-mediated persistent adaptation of oesophageal adenocarcinoma cells to HER2 inhibition




AuthorsZhang, Wei; Lang, Jiaqing; Chattrakarn, Sorayut; Wong, Chun Wai; Li, Shiyang; Kan, Karmern; Liu, Hongcai; Gu, Wenchao; Zhang, Jingwei; Westermarck, Jukka; Whitmarsh, Alan J.; Sharrocks, Andrew D.; Tournier, Cathy

PublisherSpringer Nature

Publishing placeLONDON

Publication year2025

JournalOncogene

Journal name in sourceONCOGENE

Journal acronymONCOGENE

Number of pages13

ISSN0950-9232

eISSN1476-5594

DOIhttps://doi.org/10.1038/s41388-025-03459-0

Web address https://www.nature.com/articles/s41388-025-03459-0

Self-archived copy’s web addresshttps://research.utu.fi/converis/portal/detail/Publication/499015497


Abstract
The human epidermal growth factor receptor 2 (HER2, also known as ERBB2) is a commonly over-expressed oncoprotein in oesophageal adenocarcinoma (OAC). Nonetheless, HER2-blocking agents have failed to significantly improve the outcome for OAC patients, despite achieving striking clinical success in breast cancer. To address this conundrum, we investigated how resistance progressively emerges when HER2 is targeted. We discovered that OAC cell lines that are capable of surviving in the presence of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib exhibit a significant increase in the protein level of nuclear factor erythroid 2-related factor 2 (NRF2). Indeed, NRF2 knockdown enhanced the cytotoxic effect of lapatinib, while increased NRF2 expression in OAC cells reduced their sensitivity to HER inhibition. Furthermore, prolonged overexpression of NRF2 made OAC cell lines increasingly dependent on NRF2 for growth. Further analyses indicated that the activation of NRF2-mediated transcription that was associated with lapatinib-induced persistent and resistant phenotypes coincided with a subsequent increase in glutathione metabolism. Importantly, lapatinib resistant OAC xenografts become exquisitely sensitive to pharmacological inhibition of the NRF2 pathway. Together, these findings highlight a promising therapeutic strategy for treating refractory OAC by targeting the NRF2 pathway in combination with receptor tyrosine kinase inhibition.

Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Funding information in the publication
This work was supported by a grant from Worldwide Cancer Research (#15-1283) to CT, from the Wellcome Trust (#222806/Z/21/Z and 108867/B/15/Z) to AS, and from the Sigrid Jusélius Foundation to JW.


Last updated on 2025-04-08 at 12:19